Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
VERU.US
id: 488
Christopher K. Ewing, et al. v. Veru Inc. Case
S.D. Florida
CourtOn November 9, 2022, the FDA Pulmonary-Allergy Drugs Advisory Committee voted against granting Veru’s EUA request for sabizabulin. One Committee member explained that there was “no direct evidence to support sabizabulin’s antiviral activity.”
On this news, VERU's stock price dropped over 53%, wiping out over $640 million in market capitalization.
Going back on August 11, 2022, Veru filed its Quarterly Report with the SEC, which stated that during the May 10, 2022, pre-EUA meeting, the FDA had “agreed that no additional efficacy studies were required to support a EUA application or a new drug application (NDA)” for sabizabulin, that “no additional safety data was required,” and that “the FDA agreed that the request for the EUA is supported by efficacy and safety data from our positive Phase 3 COVID-19 study . . . and no additional clinical trials are required to support an NDA submission.”
Taking all public representation into account, Veru's investors have grounds to suspect that one or more involved parties grossly breached their fiduciary duties to the Company's shareholders.
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements,
Failure to Disclose,
Malpractice,
Negligence,
Omissions
Suspected Party
Directors,
Management,
Government Authority,
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
11/09/2022
Filing date
12/05/2022
Judge
Hon. Joan A. Lenard